Upon full subscription, the Company would raise approximately SEK 75.8 m before issue expenses. The new issue is guaranteed to 66%, or SEK 50.0 m.
Specific financial information that has not been previously disclosed
The prospectus includes specific financial information regarding equity, liability and net indebtedness as of 30 November 2013, as well as cash and cash equivalents as of 8 January 2014, which has not previously been published.
As of 30 November 2013, NeuroVive’s equity was SEK 45,061,000. The Company’s cash and cash equivalents as of 30 November 2013 were SEK 8,408,000. The Company’s short-term indebtedness was SEK -7,231,000 net. Long-term indebtedness was SEK 0. Accordingly, the Company’s net indebtedness was SEK -7,231,000 as of 30 November 2013. Comprehensive information on the Company’s equity, indebtedness and net indebtedness as of 30 November 2013, is on page 46 of the prospectus.
As of 30 January 2014, the Company’s cash and cash equivalents were SEK 37.2 m. The change from 30 November 2013 above is explained by factors including the Company raising SEK 35 m via a private placement in December 2013, see pages 46-47 of the prospectus.
Prospectuses and application forms are available for download from the Company’s website www.neurovive.se/index.php/en/investors/shareholder-reports or from Erik Penser Bankaktiebolag’s website www.penser.se. An information pack, pre-printed share issue documentation and covering letter will be sent to direct-registered shareholders. Nominee-registered shareholders will only receive information packs and covering letters. Printed prospectuses and application forms are available to order free of charge via e-mail; firstname.lastname@example.org eller or by mail to Erik Penser Bankaktiebolag, Emissionsavdelningen/NeuroVive, Box 7405, 103 91 Stockholm, Sweden.
Schedule for new share issue
The record date for rights to participation in the share issue is 8 January 2014
Subscription period: 13 – 27 January 2014
Trading in subscription rights: 13 – 22 January 2014
The financial adviser to the Company for the forthcoming new share issue is Erik Penser Bankaktiebolag, which will also serve as issuing house for the new share issue. The legal adviser to the Company for the forthcoming new share issue is Advokatfirman Lindahl KB.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
Media and investor relations questions to:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or email@example.com
Please also use the above contact if you wish to arrange an interview with NeuroVive’s CEO, Mikael Brönnegård.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 6220 (switchboard), Fax: +46 (0)46 888 8348
NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this news release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 16:45. CEST on 8 January 2014.